Abbvie | Protocol M24-885
Molecule: multiple
Study title:
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn’s Disease (Target CD)
AbbVie | Protocol P23-899 (UPlift)
Molecule : Upadacitinib (Rinvoq) for moderate to severe Crohn's disease
Study Title:
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn’s Disease (CD) in Real World Clinical Practice. (UPlift)
Alimentiv | Protocol RCT-01741 (PATHFINDER) - Currently Recruiting
To compare available biologic classes as first-line treatment for achieving 1-year corticosteroid-free endoscopic remission in adult participants with moderate-to-severely active ileal or ileocolonic Crohn’s disease
Study Title:
A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn’s Disease
Agomab (Spain) | Protocol AGMB129-01-CL-201 (NOV-ERA) - Pending approbation
Molecule: Ontunisertib
Study title:
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose‑ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
Eli Lilly | Protocol MORF-057-203 (GARNET)
Study title:
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn’s Disease (GARNET)
Eli Lilly | Protocol I6T-MC-AMCE (COMMIT-CD)
Molecule: Mirikizumab
Study title:
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight (COMMIT-CD)
Janssen | Protocol CNTO1959CRD3005 (FUZION)
Molecule : Guselkumab for perianal Crohn's disease with fistula (Anti-Il23p19)
Study title:
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn’s Disease (FUZION CD)
Janssen | Protocol CNTO1959CRD3009 (CHARGE)
Molecule: multiple
Study title:
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn’s Disease (CHARGE)
Janssen | Protocol Duet Encore - CD
Molecule: JNJ-78934804 and Guselkumab
Study title:
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn’s Disease (DUET ENCORE-CD)
MERCK | Protocol MK-7240-008 - Currently Recruiting
Molecule: Tulisokibart
Study title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
Takeda | Protocol TAK-279-CD-2001 (TAK-279) - Currently Recruiting
Molecule: Oral TAK-279
Study title:
Study Title: A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease
Takeda | Protocol Vedolizumab-4051 (Explorer-CD) - Currently Recruiting
Molecule: Vedolizumab and Ustekinumab
Study title:
An Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD)